Cargando…

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial

OBJECTIVES: Tenapanor is a first-in-class, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger NHE3. This study assessed the efficacy and safety of tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). METHODS: In this phase 2, double-blind stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chey, William D, Lembo, Anthony J, Rosenbaum, David P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Functional GI Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418559/ https://www.ncbi.nlm.nih.gov/pubmed/28244495 http://dx.doi.org/10.1038/ajg.2017.41

Ejemplares similares

The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
por: Heidelbaugh, Joel J, et al.
Publicado: (2015)

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
por: Rao, Satish, et al.
Publicado: (2012)

Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome
por: Marquis, P, et al.
Publicado: (2014)

A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation
por: Chey, William D, et al.
Publicado: (2011)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation
por: Yiannakou, Yan, et al.
Publicado: (2015)

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Schoenfeld, Philip, et al.
Publicado: (2018)

Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome
por: Sayuk, Gregory S, et al.
Publicado: (2017)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
por: Chey, William D., et al.
Publicado: (2020)

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use
por: Lacy, Brian E, et al.
Publicado: (2017)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
por: Chey, William D., et al.
Publicado: (2021)

A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain
por: Jamal, M Mazen, et al.
Publicado: (2015)

Distinct Abnormalities of Small Bowel and Regional Colonic Volumes in Subtypes of Irritable Bowel Syndrome Revealed by MRI
por: Lam, Ching, et al.
Publicado: (2017)

Prucalopride Improves Bowel Function and Colonic Transit Time in Patients With Chronic Constipation: An Integrated Analysis
por: Emmanuel, Anton, et al.
Publicado: (2014)

The Epidemiology of Irritable Bowel Syndrome in the US Military: Findings from the Millennium Cohort Study
por: Riddle, Mark S, et al.
Publicado: (2016)

Association Between the Location of Diverticular Disease and the Irritable Bowel Syndrome: A Multicenter Study in Japan
por: Yamada, Eiji, et al.
Publicado: (2014)

A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
por: Miner Jr, Philip B, et al.
Publicado: (2017)

Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus
por: Rezaie, Ali, et al.
Publicado: (2017)

Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management
por: Herekar, Anam, et al.
Publicado: (2023)

Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea
por: Pattni, Sanjeev S, et al.
Publicado: (2012)

The Effect of High-Fat Diet-Induced Pathophysiological Changes in the Gut on Obesity: What Should be the Ideal Treatment?
por: Y Lee, Chooi
Publicado: (2013)

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
por: Eswaran, Shanti, et al.
Publicado: (2014)

Functional bowel symptoms, fibromyalgia and fatigue: A food-induced triad?
por: Berstad, Arnold, et al.
Publicado: (2012)

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
por: Hamatani, Tatsuto, et al.
Publicado: (2020)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Efficacy and Safety of Acupoint Catgut Embedding for Diarrhea-Predominant Irritable Bowel Syndrome and Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
por: Wu, Jing, et al.
Publicado: (2020)

Constipation-Predominant Irritable Bowel Syndrome Associated to Hyperprolactinemia
por: Seretis, C., et al.
Publicado: (2011)

Constipation-related direct medical costs in 16 887 patients newly diagnosed with chronic constipation
por: Dik, Vincent K., et al.
Publicado: (2014)

Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation
por: Mourey, Florian, et al.
Publicado: (2022)

White Matter Microstructural Similarity and Diversity of Functional Constipation and Constipation-predominant Irritable Bowel Syndrome
por: Nan, Jiaofen, et al.
Publicado: (2018)

Comparison of Quality of Life and Psychiatric Symptoms Between Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Those With Constipation-Predominant Irritable Bowel Syndrome
por: BOUSABA, J., et al.
Publicado: (2023)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Diagnostic pitfalls in functional neurological disorders
por: Pimentel, Lucio Huebra, et al.
Publicado: (2022)

The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation
por: Singh, Prashant, et al.
Publicado: (2022)

Functional Constipation and Constipation-Predominant Irritable Bowel Syndrome in the General Population: Data from the GECCO Study
por: Enck, Paul, et al.
Publicado: (2016)

Autonomic nervous system activity in constipation-predominant irritable bowel syndrome patients
por: Mazur, Marcel, et al.
Publicado: (2012)

Methane and Constipation-predominant Irritable Bowel Syndrome: Entwining Pillars of Emerging Neurogastroenterology
por: Bin Waqar, Syed Hamza, et al.
Publicado: (2019)

Prevalence of Subthreshold Depression Among Constipation-Predominant Irritable Bowel Syndrome Patients
por: Mokhtar, Norfilza Mohd, et al.
Publicado: (2020)

Efficacy and Mechanism of Trimebutine Maleate Combined with Lactulose in the Treatment of Constipation-Predominant Irritable Bowel Syndrome in the Elderly
por: Zhou, Yeping, et al.
Publicado: (2022)

A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
por: Johansson, Susanne, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6hc9jjtugesaukhp69krjhskg3